Louis Aronne is a paid consultant and advisory board member for Eli Lilly and Company, the study sponsor and the manufacturer of orforglipron and tirzepatide.
[1] [8] The combined stimulation of these three pathways is intended to create a synergistic effect on appetite suppression, caloric intake reduction, and metabolic rate
Park JR, et al
Tirzepatide: How They Work Both Semaglutide and Tirzepatide are glucagon-like peptide-1 (GLP-1) receptor agonists, which means that they mimic the GLP-1 hormone our bodies naturally create
As patients lose weight and gain metabolic control, many report the return of regular menstrual cycles and more predictable ovulation
That recognition is richly deserved, since it is unclear if the GLP-1 drug path to obesity treatment, and all of the associated benefits, would have been seen at this time without her influence